The effects of glucocorticoids on neuropathic pain: a review with emphasis on intrathecal methylprednisolone acetate delivery.
Guangrui Lai, Jingjing Wu, Xiaoliang Liu, Yanyan Zhao
Index: Anesth. Analg. 118(5) , 1097-112, (2014)
Full Text: HTML
Abstract
Methylprednisolone acetate (MPA) has a long history of use in the treatment of sciatic pain and other neuropathic pain syndromes. In several of these syndromes, MPA is administered in the epidural space. On a limited basis, MPA has also been injected intrathecally in patients suffering from postherpetic neuralgia and complex regional pain syndrome. The reports on efficacy of intrathecal administration of MPA in neuropathic pain patients are contradictory, and safety is debated. In this review, we broadly consider mechanisms whereby glucocorticoids exert their action on spinal cascades relevant to the pain arising after nerve injury and inflammation. We then focus on the characteristics of the actions of MPA in pharmacokinetics, efficacy, and safety when administered in the intrathecal space.
Related Compounds
Related Articles:
2010-01-01
[Chem. Res. Toxicol. 23 , 171-83, (2010)]
2015-07-01
[Clin. Chem. Lab Med. 53 , 1259-64, (2015)]
2011-12-01
[J. Sci. Ind. Res. 65(10) , 808, (2006)]
Simultaneous quantification of seven hippocampal neurotransmitters in depression mice by LC-MS/MS.
2014-05-30
[J. Neurosci. Methods 229 , 8-14, (2014)]
2014-08-01
[Clin. Ther. 36(8) , 1264-72, (2014)]